Stephens resumed coverage of BioLife Solutions (BLFS) with an Overweight rating and $30 price target and named the stock as the analyst’s “Best Idea.” BioLife is now positioned as more consumable-focused and closely aligned with the cell and gene therapy industry following the sale of SciSafe, CBS, and Stirling, the analyst tells investors. The Media segment “represents a crown jewel asset” as it has about 70% market share and high-60%-plus gross margins, serving as the key growth driver in the near-term, the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.